Provided by Tiger Trade Technology Pte. Ltd.

Contineum Therapeutics, INC.

15.00
+0.52003.59%
Post-market: 15.000.00000.00%17:43 EST
Volume:424.04K
Turnover:6.37M
Market Cap:547.94M
PE:-6.68
High:15.46
Open:14.48
Low:14.39
Close:14.48
52wk High:15.48
52wk Low:3.35
Shares:36.53M
Float Shares:24.03M
Volume Ratio:1.30
T/O Rate:1.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2459
EPS(LYR):-2.1836
ROE:-30.40%
ROA:-20.89%
PB:3.04
PE(LYR):-6.87

Loading ...

Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain Reports Sale of Common Shares

Reuters
·
Feb 06

Contineum Therapeutics CMO Tim Watkins Reports Sale of Common Shares

Reuters
·
Jan 31

BRIEF-Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule

Reuters
·
Jan 29

Contineum Therapeutics Grants Stock Options to New Employee Under Inducement Plan

Reuters
·
Jan 29

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jan 29

Contineum Therapeutics Launches 2026 Inducement Equity Incentive Plan

Reuters
·
Jan 27

Morgan Stanley Downgrades Contineum Therapeutics to Equalweight From Overweight, Adjusts Price Target to $14 From $23

MT Newswires Live
·
Jan 08

Contineum Therapeutics Cut to Equal-Weight From Overweight by Morgan Stanley

Dow Jones
·
Jan 08

Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain Reports Sale of Common Shares

Reuters
·
Jan 07

Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain Reports Disposal of Common Shares

Reuters
·
Dec 31, 2025

Contineum Therapeutics Prices Upsized $90 Million Class A Share Offering

MT Newswires Live
·
Dec 12, 2025

BRIEF-Contineum Therapeutics Prices Upsized $90 Million Public Offering At $12.25 Per Share

Reuters
·
Dec 12, 2025

Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering

THOMSON REUTERS
·
Dec 12, 2025

Contineum Therapeutics Inc - Offering of 7.3 Mln Shares at $12.25 per Share

THOMSON REUTERS
·
Dec 12, 2025

BUZZ-Contineum Therapeutics falls on planned $75 million share sale

Reuters
·
Dec 12, 2025

Contineum Therapeutics Inc - Phase 2 Trial for Pipe-791 Expected to Be Completed in June 2028 - SEC Filing

THOMSON REUTERS
·
Dec 12, 2025

Contineum Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
Nov 24, 2025

Contineum price target lowered to $14 from $16 at Baird

TIPRANKS
·
Nov 24, 2025

Contineum Shares Fall After Phase 2 PIPE-307 Trial Fails to Meet Efficacy Goals in Multiple Sclerosis

MT Newswires Live
·
Nov 22, 2025

Contineum Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
Nov 21, 2025